Frank Yocca, Chief Scientific Officer at BioXcel Therapeutics, Inc. (BTAI), sold 27,600 shares at $55.88 ($1.6M) on 2021-02-16, disclosed to the SEC on 2021-02-18.
Open-market sale of $1.6M BTAI by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $55.88 | 1,300 | $73K | 4.6% |
| 2 | $56.49 | 6,805 | $384K | 24.2% |
| 3 | $56.49 | 6,805 | $384K | 24.2% |
| 4 | $57.71 | 1,137 | $66K | 4.1% |
| 5 | $57.71 | 1,137 | $66K | 4.1% |
| 6 | $58.54 | 2,886 |
| $169K |
| 10.6% |
| 7 | $58.54 | 2,886 | $169K | 10.6% |
| 8 | $59.46 | 500 | $30K | 1.9% |
| 9 | $60.43 | 1,772 | $107K | 6.7% |
| 10 | $60.43 | 1,772 | $107K | 6.7% |
| 11 | $61.20 | 600 | $37K | 2.3% |
| Total | $57.65 avg | 27,600 | $1.6M | 100% |
| Filing → |
| BTAI | SELL | 2024-10-03 | $4K | — | Filing → |
| BTAI | SELL | 2024-09-17 | $245 | — | Filing → |
| BTAI | SELL | 2024-06-18 | $476 | — | Filing → |